Sign inJoin waitlistJoin the waitlist

Hamid Sayar

Professor of Clinical Medicine · Indiana University School of Medicine

Credentials: · · · · · · ·

History

Indiana University School of Medicine
Present

Research

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
New England Journal of Medicine · 2020 · 352 citations
Where west meets east: the complex mtDNA landscape of the southwest and Central Asian corridor
The American Journal of Human Genetics · 2004 · 280 citations
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind,…
The Lancet Oncology · 2015 · 137 citations

Larry Cripe
8 papers
Gail Roboz
5 papers
BS
Barry Skikne
4 papers
Heiko Konig
4 papers
HB
Howard Boswell
4 papers
Guillermo Garcia-Manero
3 papers
Hagop Kantarjian
3 papers
IR
Ian Rabinowitz
3 papers
Olatoyosi Odenike
3 papers
Robert Stuart
3 papers
Antoine Saliba
2 papers · 2 as a fellow
Attaya Suvannasankha
2 papers

Clinical trials

Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
Principal investigator · Terminated
Hamid Sayar
2015–2017
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Principal investigator · Completed · Phase 1, Phase 2
Hamid Sayar
2012–2017
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
Indiana University
2010–2012
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Principal investigator · Completed · Phase 1
Indiana University
2009–2013